BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancerinitiating cells

Elisabet Cuyàs, Bruna Corominas-Faja, María Muñoz San Martín, Begoña Martin-Castillo, Ruth Lupu, Joan Brunet, Joaquim Bosch-Barrera, Javier A. Menendez

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Denosumab, a monoclonal antibody to the receptor activator of nuclear factor-κB ligand (RANKL), might be a novel preventative therapy for BRCA1-mutation carriers at high risk of developing breast cancer. Beyond its well-recognized bone-targeted activity impeding osteoclastogenesis, denosumab has been proposed to interfere with the cross-talk between RANKL-producing sensor cells and cancer-initiating RANK+ responder cells that reside within premalignant tissues of BRCA1-mutation carriers. We herein tested the alternative but not mutually exclusive hypothesis that BRCA1 deficiency might cell-autonomously activate RANKL expression to generate cellular states with cancer stem cell (CSC)-like properties. Using isogenic pairs of normallike human breast epithelial cells in which the inactivation of a single BRCA1 allele results in genomic instability, we assessed the impact of BRCA1 haploinsufficiency on the expression status of RANK and RANKL. RANK expression remained unaltered but RANKL was dramatically up-regulated in BRCA1mut/+ haploinsufficient cells relative to isogenic BRCA1+/+ parental cells. Neutralizing RANKL with denosumab significantly abrogated the ability of BRCA1 haploinsufficient cells to survive and proliferate as floating microtumors or "mammospheres" under non-adherent/non-differentiating conditions, an accepted surrogate of the relative proportion and survival of CSCs. Intriguingly, CSC-like states driven by epithelial-to-mesenchymal transition or HER2 overexpression traits responded to some extent to denosumab. We propose that breast epithelium-specific mono-allelic inactivation of BRCA1 might suffice to cellautonomously generate RANKL-addicted, denosumab-responsive CSC-like states. The convergent addiction to a hyperactive RANKL/RANK axis of CSC-like states from genetically diverse breast cancer subtypes might inaugurate a new era of cancer prevention and treatment based on denosumab as a CSC-targeted agent.

Original languageEnglish (US)
Pages (from-to)35019-35032
Number of pages14
JournalOncotarget
Volume8
Issue number21
DOIs
StatePublished - 2017

Fingerprint

Haploinsufficiency
Neoplastic Stem Cells
Breast
Breast Neoplasms
Mutation
Epithelial-Mesenchymal Transition
Genomic Instability
Cytoplasmic and Nuclear Receptors
Osteogenesis
Denosumab
Neoplasms
Epithelium
Epithelial Cells
Alleles
Monoclonal Antibodies
Ligands
Bone and Bones
Survival

Keywords

  • BRCA1
  • Cancer stem cells
  • Denosumab
  • RANK
  • RANKL

ASJC Scopus subject areas

  • Oncology

Cite this

Cuyàs, E., Corominas-Faja, B., Martín, M. M. S., Martin-Castillo, B., Lupu, R., Brunet, J., ... Menendez, J. A. (2017). BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancerinitiating cells. Oncotarget, 8(21), 35019-35032. https://doi.org/10.18632/oncotarget.16558

BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancerinitiating cells. / Cuyàs, Elisabet; Corominas-Faja, Bruna; Martín, María Muñoz San; Martin-Castillo, Begoña; Lupu, Ruth; Brunet, Joan; Bosch-Barrera, Joaquim; Menendez, Javier A.

In: Oncotarget, Vol. 8, No. 21, 2017, p. 35019-35032.

Research output: Contribution to journalArticle

Cuyàs, E, Corominas-Faja, B, Martín, MMS, Martin-Castillo, B, Lupu, R, Brunet, J, Bosch-Barrera, J & Menendez, JA 2017, 'BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancerinitiating cells', Oncotarget, vol. 8, no. 21, pp. 35019-35032. https://doi.org/10.18632/oncotarget.16558
Cuyàs, Elisabet ; Corominas-Faja, Bruna ; Martín, María Muñoz San ; Martin-Castillo, Begoña ; Lupu, Ruth ; Brunet, Joan ; Bosch-Barrera, Joaquim ; Menendez, Javier A. / BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancerinitiating cells. In: Oncotarget. 2017 ; Vol. 8, No. 21. pp. 35019-35032.
@article{508ca99e2e7a49b393e559e8f3f655c1,
title = "BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancerinitiating cells",
abstract = "Denosumab, a monoclonal antibody to the receptor activator of nuclear factor-κB ligand (RANKL), might be a novel preventative therapy for BRCA1-mutation carriers at high risk of developing breast cancer. Beyond its well-recognized bone-targeted activity impeding osteoclastogenesis, denosumab has been proposed to interfere with the cross-talk between RANKL-producing sensor cells and cancer-initiating RANK+ responder cells that reside within premalignant tissues of BRCA1-mutation carriers. We herein tested the alternative but not mutually exclusive hypothesis that BRCA1 deficiency might cell-autonomously activate RANKL expression to generate cellular states with cancer stem cell (CSC)-like properties. Using isogenic pairs of normallike human breast epithelial cells in which the inactivation of a single BRCA1 allele results in genomic instability, we assessed the impact of BRCA1 haploinsufficiency on the expression status of RANK and RANKL. RANK expression remained unaltered but RANKL was dramatically up-regulated in BRCA1mut/+ haploinsufficient cells relative to isogenic BRCA1+/+ parental cells. Neutralizing RANKL with denosumab significantly abrogated the ability of BRCA1 haploinsufficient cells to survive and proliferate as floating microtumors or {"}mammospheres{"} under non-adherent/non-differentiating conditions, an accepted surrogate of the relative proportion and survival of CSCs. Intriguingly, CSC-like states driven by epithelial-to-mesenchymal transition or HER2 overexpression traits responded to some extent to denosumab. We propose that breast epithelium-specific mono-allelic inactivation of BRCA1 might suffice to cellautonomously generate RANKL-addicted, denosumab-responsive CSC-like states. The convergent addiction to a hyperactive RANKL/RANK axis of CSC-like states from genetically diverse breast cancer subtypes might inaugurate a new era of cancer prevention and treatment based on denosumab as a CSC-targeted agent.",
keywords = "BRCA1, Cancer stem cells, Denosumab, RANK, RANKL",
author = "Elisabet Cuy{\`a}s and Bruna Corominas-Faja and Mart{\'i}n, {Mar{\'i}a Mu{\~n}oz San} and Bego{\~n}a Martin-Castillo and Ruth Lupu and Joan Brunet and Joaquim Bosch-Barrera and Menendez, {Javier A.}",
year = "2017",
doi = "10.18632/oncotarget.16558",
language = "English (US)",
volume = "8",
pages = "35019--35032",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "21",

}

TY - JOUR

T1 - BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancerinitiating cells

AU - Cuyàs, Elisabet

AU - Corominas-Faja, Bruna

AU - Martín, María Muñoz San

AU - Martin-Castillo, Begoña

AU - Lupu, Ruth

AU - Brunet, Joan

AU - Bosch-Barrera, Joaquim

AU - Menendez, Javier A.

PY - 2017

Y1 - 2017

N2 - Denosumab, a monoclonal antibody to the receptor activator of nuclear factor-κB ligand (RANKL), might be a novel preventative therapy for BRCA1-mutation carriers at high risk of developing breast cancer. Beyond its well-recognized bone-targeted activity impeding osteoclastogenesis, denosumab has been proposed to interfere with the cross-talk between RANKL-producing sensor cells and cancer-initiating RANK+ responder cells that reside within premalignant tissues of BRCA1-mutation carriers. We herein tested the alternative but not mutually exclusive hypothesis that BRCA1 deficiency might cell-autonomously activate RANKL expression to generate cellular states with cancer stem cell (CSC)-like properties. Using isogenic pairs of normallike human breast epithelial cells in which the inactivation of a single BRCA1 allele results in genomic instability, we assessed the impact of BRCA1 haploinsufficiency on the expression status of RANK and RANKL. RANK expression remained unaltered but RANKL was dramatically up-regulated in BRCA1mut/+ haploinsufficient cells relative to isogenic BRCA1+/+ parental cells. Neutralizing RANKL with denosumab significantly abrogated the ability of BRCA1 haploinsufficient cells to survive and proliferate as floating microtumors or "mammospheres" under non-adherent/non-differentiating conditions, an accepted surrogate of the relative proportion and survival of CSCs. Intriguingly, CSC-like states driven by epithelial-to-mesenchymal transition or HER2 overexpression traits responded to some extent to denosumab. We propose that breast epithelium-specific mono-allelic inactivation of BRCA1 might suffice to cellautonomously generate RANKL-addicted, denosumab-responsive CSC-like states. The convergent addiction to a hyperactive RANKL/RANK axis of CSC-like states from genetically diverse breast cancer subtypes might inaugurate a new era of cancer prevention and treatment based on denosumab as a CSC-targeted agent.

AB - Denosumab, a monoclonal antibody to the receptor activator of nuclear factor-κB ligand (RANKL), might be a novel preventative therapy for BRCA1-mutation carriers at high risk of developing breast cancer. Beyond its well-recognized bone-targeted activity impeding osteoclastogenesis, denosumab has been proposed to interfere with the cross-talk between RANKL-producing sensor cells and cancer-initiating RANK+ responder cells that reside within premalignant tissues of BRCA1-mutation carriers. We herein tested the alternative but not mutually exclusive hypothesis that BRCA1 deficiency might cell-autonomously activate RANKL expression to generate cellular states with cancer stem cell (CSC)-like properties. Using isogenic pairs of normallike human breast epithelial cells in which the inactivation of a single BRCA1 allele results in genomic instability, we assessed the impact of BRCA1 haploinsufficiency on the expression status of RANK and RANKL. RANK expression remained unaltered but RANKL was dramatically up-regulated in BRCA1mut/+ haploinsufficient cells relative to isogenic BRCA1+/+ parental cells. Neutralizing RANKL with denosumab significantly abrogated the ability of BRCA1 haploinsufficient cells to survive and proliferate as floating microtumors or "mammospheres" under non-adherent/non-differentiating conditions, an accepted surrogate of the relative proportion and survival of CSCs. Intriguingly, CSC-like states driven by epithelial-to-mesenchymal transition or HER2 overexpression traits responded to some extent to denosumab. We propose that breast epithelium-specific mono-allelic inactivation of BRCA1 might suffice to cellautonomously generate RANKL-addicted, denosumab-responsive CSC-like states. The convergent addiction to a hyperactive RANKL/RANK axis of CSC-like states from genetically diverse breast cancer subtypes might inaugurate a new era of cancer prevention and treatment based on denosumab as a CSC-targeted agent.

KW - BRCA1

KW - Cancer stem cells

KW - Denosumab

KW - RANK

KW - RANKL

UR - http://www.scopus.com/inward/record.url?scp=85019963624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019963624&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.16558

DO - 10.18632/oncotarget.16558

M3 - Article

AN - SCOPUS:85019963624

VL - 8

SP - 35019

EP - 35032

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 21

ER -